» Articles » PMID: 11090484

Mechanism Related to Reduction of Intraocular Pressure by Melanocortins in Rabbits

Overview
Journal Br J Ophthalmol
Specialty Ophthalmology
Date 2000 Nov 25
PMID 11090484
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To investigate whether the ocular hypotensive effect of alpha melanocyte stimulating hormone (MSH) is related to eicosanoids or cyclic AMP (cAMP).

Methods: Intraocular pressure (IOP) readings were taken at a similar time on the day before and after a single dose of topical MSH. Changes in the levels of prostaglandin E(2) (PGE(2)) and prostacyclin in incubated iris ciliary body (ICB) explants were measured by specific radioimmunoassay (RIA). Incubated ICB explants were exposed to MSH or adrenaline (epinephrine) for a week. In addition, cAMP levels in the medium were determined following short term incubation using RIA.

Results: A significant dose related reduction in IOP was noted with topical MSH (mean (SD) maximal effect 4.5 (0.1) mm Hg (21%); p<0.001 v appropriate baseline) which persisted up to 6 hours (p=0.05). MSH treated ICB explants showed a 1.5-fold increase in PGE(2) and prostacyclin levels (p<0.001 for each parameter) while cAMP levels were increased twofold (p<0.001).

Conclusions: A single application of MSH caused a sustained dose related ocular hypotensive effect with no side effects. An increase in eicosanoid and cAMP levels following ICB exposure to MSH indicated their involvement in MSH induced ocular hypotension. MSH and its analogues might have clinical relevance as antiglaucoma drugs with fewer side effects because of their antiallergic and anti-inflammatory properties.

Citing Articles

Therapeutic Effect of α-MSH in Primary Cultured Orbital Fibroblasts Obtained from Patients with Thyroid Eye Disease.

Cheng P, Tsai P, Tai M, Bee Y Int J Mol Sci. 2021; 22(20).

PMID: 34681884 PMC: 8537628. DOI: 10.3390/ijms222011225.


The Role of Alpha-MSH as a Modulator of Ocular Immunobiology Exemplifies Mechanistic Differences between Melanocortins and Steroids.

Clemson C, Yost J, Taylor A Ocul Immunol Inflamm. 2016; 25(2):179-189.

PMID: 26807874 PMC: 5769144. DOI: 10.3109/09273948.2015.1092560.


Applications of the role of α-MSH in ocular immune privilege.

Taylor A, Lee D Adv Exp Med Biol. 2011; 681:143-9.

PMID: 21222267 PMC: 3329275. DOI: 10.1007/978-1-4419-6354-3_12.

References
1.
Goland R, Conwell I, Warren W, Wardlaw S . Placental corticotropin-releasing hormone and pituitary-adrenal function during pregnancy. Neuroendocrinology. 1992; 56(5):742-9. DOI: 10.1159/000126302. View

2.
Camras C, Schumer R, Marsk A, Lustgarten J, Serle J, Stjernschantz J . Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch Ophthalmol. 1992; 110(12):1733-8. DOI: 10.1001/archopht.1992.01080240073034. View

3.
Mauri A, Volpe A, Martellotta M, Barra V, Piu U, Angioni G . alpha-Melanocyte-stimulating hormone during human perinatal life. J Clin Endocrinol Metab. 1993; 77(1):113-7. DOI: 10.1210/jcem.77.1.8392079. View

4.
Goodall T, Buffey J, Rennie I, Benson M, Parsons M, Faulkner M . Effect of melanocyte stimulating hormone on human cultured choroidal melanocytes, uveal melanoma cells, and retinal epithelial cells. Invest Ophthalmol Vis Sci. 1994; 35(3):826-37. View

5.
Ceriani G, Macaluso A, Catania A, Lipton J . Central neurogenic antiinflammatory action of alpha-MSH: modulation of peripheral inflammation induced by cytokines and other mediators of inflammation. Neuroendocrinology. 1994; 59(2):138-43. DOI: 10.1159/000126650. View